Current treatments for atopic dermatitis in Japan. Issue 2 (30th December 2020)

• Record Type: Journal Article
• Authors: Miyano, Kyohei; Tsunemi, Yuichiro
• Is Part Of: Journal of dermatology. Volume 48:Issue 2(2021)
• Page Start: 140
• Page End: 151
• Publication Date: 2020-12-30
• Subjects: atopic dermatitis -- corticosteroid -- delgocitinib -- dupilumab -- tacrolimus; Dermatology -- Periodicals; Dermatology -- Japan -- Periodicals; Skin -- Diseases -- Periodicals; 616.5005
• DOI: 10.1111/1346-8138.15730
• Languages: English
• ISSNs: 0385-2407

Abstract

Abstract: The goal of a treatment regimen for atopic dermatitis is to reach and maintain a state where the patient exhibits mild symptoms or an absence of symptoms, and the patient should not experience disturbance during daily activities. The basis of a treatment regimen for atopic dermatitis is topical therapy, and currently there exist topical corticosteroids, tacrolimus and delgocitinib. Using these, proactive therapy is performed as maintenance therapy after remission induction therapy. However, in cases of moderate to severe atopic dermatitis, topical drugs alone cannot induce remission and systemic therapies such as cyclosporin, ultraviolet therapy, and dupilumab should be used in combination. In particular, dupilumab has many advantages such as high efficacy, relatively few adverse reactions, and ease of use in elderly patients with severe atopic dermatitis. In this review, we present a treatment algorithm for atopic dermatitis that emphasizes the importance of maintaining remission after induction of remission, and summarizes the characteristics of current medication therapy for atopic dermatitis in Japan.